Assessment of myeloid response and iron status among Sudanese pediatric ESKD on hemodialysis through reticulocyte parameters and β-globin mRNA expression

BMC Nephrol. 2024 Oct 26;25(1):380. doi: 10.1186/s12882-024-03806-5.

Abstract

Background: Sudanese children with End-Stage Kidney Disease (ESKD) often show limited improvement in hemoglobin levels despite treatment with recombinant human erythropoietin (rHuEPO). This study aims to assess the response to rHuEPO therapy by analyzing β-globin mRNA expression and reticulocyte parameters. Additionally, it classifies anemia among Sudanese pediatric patients based on iron status, considering age and gender as biological markers for evaluating treatment response.

Methods: A prospective observational cohort study was conducted from January 2019 to February 2020 in Khartoum, Sudan, involving 45 anemic children aged 2 to 15 years diagnosed with ESKD. The treatment protocol included rHuEPO injections and maintenance hemodialysis. Laboratory assessments consisted of complete blood count (CBC), absolute reticulocyte count, ferritin, and transferrin measurements. β-globin mRNA expression was quantified using reverse transcription polymerase chain reaction (RT-PCR), and reticulocyte parameters, including Reticulocyte Hemoglobin Content (CHr), percentage of hypochromic reticulocytes (HYPO%), and Immature Reticulocyte Fraction (IRF), were measured via flow cytometry.

Results: Significant variations in hemoglobin levels were observed across different age groups (p = 0.011). Gender analysis revealed a significant association with IRF, showing a lower IRF in male patients (p = 0.017). However, there were no significant differences in hemoglobin levels between genders (p = 0.999). β-globin mRNA expression showed considerable variability, with a strong positive correlation with hemoglobin levels (r = 0.875, p < 0.0001).

Conclusion: Age and gender significantly influence treatment responses in children with ESKD, highlighting the need to consider growth physiology in anemia management. This study underscores the variability in β-globin mRNA expression and its association with Flow Cytometry parameters, demonstrating their effectiveness in evaluating iron status and guiding rHuEPO dosage.

Keywords: End-stage kidney disease (ESKD); Ferritin; Flow cytometry; Hypochromic cells (HYPO%); Immature reticulocyte fraction (IRF); Reticulocyte hemoglobin content (CHr); Sudanese children; β-globin mRNA expression.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Anemia / genetics
  • Child
  • Child, Preschool
  • Erythropoietin* / therapeutic use
  • Female
  • Ferritins / blood
  • Hemoglobins / analysis
  • Hemoglobins / metabolism
  • Humans
  • Iron*
  • Kidney Failure, Chronic* / blood
  • Kidney Failure, Chronic* / therapy
  • Male
  • Prospective Studies
  • RNA, Messenger*
  • Recombinant Proteins / therapeutic use
  • Renal Dialysis*
  • Reticulocyte Count
  • Reticulocytes* / metabolism
  • Sudan
  • Transferrin / metabolism
  • beta-Globins* / genetics

Substances

  • RNA, Messenger
  • beta-Globins
  • Erythropoietin
  • Iron
  • Recombinant Proteins
  • Hemoglobins
  • Transferrin
  • Ferritins